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ABSTRACT
The combination of protein-coated graphene oxide (GO) and microencapsulation technology has
moved a step forward in the challenge of improving long-term alginate encapsulated cell survival and
sustainable therapeutic protein release, bringing closer its translation from bench to the clinic.
Although this new approach in cell microencapsulation represents a great promise for long-term
drug delivery, previous studies have been performed only with encapsulated murine C2C12 myoblasts
genetically engineered to secrete murine erythropoietin (C2C12-EPO) within 160mm diameter hybrid
alginate protein-coated GO microcapsules implanted into syngeneic mice. Here, we show that encapsu-
lated C2C12-EPO myoblasts survive longer and release more therapeutic protein by doubling the
micron diameter of hybrid alginate-protein-coated GO microcapsules to 380mm range. Encapsulated
mesenchymal stem cells (MSC) genetically modified to secrete erythropoietin (D1-MSCs-EPO) within
380mm-diameter hybrid alginate-protein-coated GO microcapsules confirmed this improvement in sur-
vival and sustained protein release in vitro. This improved behavior is reflected in the hematocrit
increase of allogeneic mice implanted with both encapsulated cell types within 380mm diameter
hybrid alginate-protein-coated GO microcapsules, showing lower immune response with encapsulated
MSCs. These results provide a new relevant step for the future clinical application of protein-coated
GO on cell microencapsulation.
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Alginate microencapsulated cell-based therapies can provide
the sustained release of therapeutic products in the
treatment of a variety of diseases. Cells are considered micro-
encapsulated when they are entrapped within a
semipermeable polymer matrix at the micrometer scale, pre-
venting both migration of the entrapped cells and invasion
of host immune responders. The pores of the encapsulating
polymer are large enough to permit the ingress of nutrients,
oxygen, and electrolytes and the egress of molecules pro-
duced by entrapped cells, such as hormones, metabolites,
and waste products. Larger host immune responders such as
cells, immunoglobulins and complement cannot penetrate
the microcapsules walls and are, therefore, hindered from
interacting with surface antigens on microencapsulated cells
(Orive et al., 2005; Prakash & Jones, 2005), allowing their
immunoisolation.
Currently, several challenges in cell therapy using microen-
capsulated cells need to be overcome, such as the decrease
of the dying cell number inside the microcapsules or the
enhancement of the sustained protein release from encapsu-
lated cells, achieving long-lasting treatments. In this regard,
we combined cell microencapsulation technology with
graphene oxide (GO), a highly oxidized form of chemically
modified graphene, consisting of a single atom thick layer of
graphene sheets with carboxylic acid, epoxide, and hydroxyl
groups (Goenka et al., 2013). We incorporated different
concentrations of GO into 160mm diameter alginate microcap-
sules, showing that GO concentrations between 25 and 50mg/
ml increased the viability, metabolic activity, membrane integ-
rity, and erythropoietin (EPO) release of encapsulated murine
C2C12 myoblasts genetically engineered to secrete murine
erythropoietin (C2C12-EPO) (Ciriza et al., 2015), improving even
more by the formation of a protein bio-corona with fetal
bovine serum (FBS) (Saenz Del Burgo et al., 2017).
CONATCT Jesus Ciriza jeciriza@gmail.com; Jose Luis Pedraz joseluis.pedraz@ehu.eus NanoBioCel Group, Laboratory of Pharmacy and Pharmaceutical
Technology, Faculty of Pharmacy, University of the Basque Country UPV/EHU, Paseo de la Universidad 7, Vitoria-Gasteiz 01006, SpainThese authors contributed equally to this work.
Supplemental data for this article can be accessed here.
 2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
DRUG DELIVERY
2018, VOL. 25, NO. 1, 1147–1160
https://doi.org/10.1080/10717544.2018.1474966
This increment in EPO release was reflected in vivo by an
enhancement of hematocrit levels after implantation in syn-
geneic mice of 160mm diameter hybrid alginate-protein-
coated GO (50mg/ml) microcapsules containing C2C12-EPO
myoblasts (Saenz Del Burgo et al., 2017). However, other cell
types should be assessed both in vitro and in vivo (Ciriza et al.,
2015), to confirm the successful results demonstrated by com-
bining alginate microcapsule technology with GO.
Another challenge in cell therapy using microencapsulated
cells is the size of microcapsules. The combination of alginate
microencapsulation and GO initially was performed within
160mm diameter microcapsules (Ciriza et al., 2015; Saenz Del
Burgo et al., 2017) because small-sized microcapsules showed
better surface/volume ratio, reduced mass transport limita-
tions, and enhanced biocompatibility (Robitaille et al., 1999;
Sugiura et al., 2007), with faster ingress and egress of mole-
cules (Wilson & Chaikof, 2008; Sakai & Kawakami, 2010).
Although diameters from 100 mm of alginate microcapsules
have been widely used for in vivo applications, such as con-
trolled drug release or systems for tissue regeneration
(Whelehan & Marison, 2011; Lee & Mooney, 2012), bigger
diameters between 300mm and 1mm have been more exten-
sively evaluated in clinical application for the last four deca-
des, such as the immune isolation of donor pancreatic islets
for the treatment of type-1 diabetes (Lim & Sun, 1980). In
this sense, it is relevant to determine the behavior of encap-
sulated cells within hybrid alginate-protein-coated GO micro-
capsules with diameter bigger than 300 mm.
Finally, the foreign body response against biomaterial is
an important challenge to overcome. The immune rejection
of alginate encapsulated cells is not always completely
bypassed by alginate microcapsules. For example, CD4þ
T cells, B cells, and macrophages can secrete immune mole-
cules and complement that traverse microcapsules destroy-
ing the inner encapsulated xenograft cells (Kobayashi et al.,
2006). Moreover, the biomaterial is often immune recognized,
initiating a cascade of cellular processes to lead the foreign
body reaction (Anderson et al., 2008; Williams, 2008). These
processes consist on inflammation, formation of fused macro-
phages that generate foreign body giant cells, and fibrosis,
that finally builds up a 100-mm thick fibrotic tissue envelop-
ing the implanted biomaterial and affecting the functionality
of the device (Ratner, 2002). In this regard, mesenchymal
stem cells (MSCs) have arisen great interest in the last deca-
des, due to their immunomodulatory properties (Rasmusson,
2006; Uccelli et al., 2006). They have been examined in a var-
iety of animal models related to alloreactive immunity (organ
and stem cell transplantation), autoimmunity, or tumor
immunity. The first systemic infusion of allogeneic baboon-
bone marrow-MSCs prolonged allogeneic skin grafts survival
from 7 to 11 d, compared to animals non-infused with MSCs
(Bartholomew et al., 2002). Interestingly, MSC immunomodu-
latory capacity is altered in 3-D culture systems, together
with phenotypic cellular changes, having high potential for
tissue engineering and cellular therapies. For example, MSCs
within alginate hydrogels inhibit phytohemaglutinin-
stimulated peripheral blood mononuclear cell proliferation
more than monolayer-MSCs (Follin et al., 2015), or co-cultures
of rat organotypic hippocampal slides with MSCs embedded
into an alginate hydrogel, reduce TNF-a inflammation more
than co-cultures with non-embedded MSCs (Stucky et al.,
2015). MSCs, therefore, do not only directly participate in
tissue repair and regeneration but also may modulate the
host foreign body response toward the engineered construct,
holding a great promise in tissue engineering.
In summary, three main challenges with hybrid alginate-
protein-coated GO microcapsules remain untested: (1) the
encapsulation with new cell types, (2) the effect of the micro-
capsule size, and (3) the circumvention of the foreign body
reaction. Therefore, we aimed to study how increasing the
diameter size of hybrid alginate-protein-coated GO microcap-
sules from 160 to 380 mm would affect the viability and func-
tionality of encapsulated C2C12-EPO myoblasts, further
studying this effect with encapsulated MSCs. Next, we com-
pared the in vivo beneficial effects after implantation of
encapsulated C2C12-EPO and MSCs genetically modified to
secrete EPO (D1-MSCs-EPO) within both diameter size algin-
ate-protein-coated GO alginate microcapsules into allogeneic
mice, confirming a lack of foreign body reaction increment




GO 3wt% was kindly provided by Graphenea Company (San
Sebastian, Spain). The product was suspended in FBS (Gibco,
Waltham, MA, USA) and sonicated for 1 h in order to obtain a
higher percentage of monolayer flakes. Ultra pure low-viscos-
ity (20–200mPas) and high guluronic (LVG) sodium alginate
(G/M ratio 1.5) with MW of 75–200 kDa was purchased from
FMC Biopolymer (NovaMatrix, Sandvika, Norway). Poly-L-lysine
hydrobromide (PLL, 15-30 kDa) was purchased from Sigma-
Aldrich (St Louis, MO, USA).
The following monoclonal antibodies were purchased from
BioLegend (San Diego, CA, USA) and used in flow cytometry:
PE-Cy7 conjugated anti CD45 (I3/2.3), FITC-conjugated anti-
CD3 (17A2), PE conjugated anti-CD4 (RM4-4), APC conjugated
anti-CD8 (53-6.7), APC conjugated anti-CD11b (M1/70), PE
conjugated anti-CD19 (6D5), APC-Cy7 conjugated anti-NK1.1
(PK136), PE-Cy7 conjugated Rat IgG2b, j Isotype Ctrl
(RTK4530), APC-Cy7 conjugated Mouse IgG2a, j Isotype Ctrl
(MOPC-173), FITC conjugated Rat IgG2b, j Isotype
Ctrl(RTK4530), PE conjugated Rat IgG2b, j Isotype Ctrl
(RTK4530), PE conjugated Rat IgG2a, j Isotype Ctrl (RTK2758),
APC conjugated Rat IgG2a, j Isotype Ctrl (RTK2758), APC con-
jugated Rat IgG2b, j Isotype Ctrl (RTK4530). Each antibody
was carefully titrated and used at a concentration that gave
the highest signal with the lowest background, following
staining of splenocytes single cell suspensions.
Cell culture
Murine C2C12 genetically engineered to secrete murine
erythropoietin (C2C12-EPO) (Murua et al., 2009) were grown in
T-flasks with Dulbecco’s modified Eagles’s medium (DMEM;
Gibco) supplemented with inactivated 10% FBS (Gibco),
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2mM L-glutamine (Gibco) and 1% antibiotic/antimycotic solu-
tion (Gibco) at 37 C in humidified 5% CO2/95% air atmos-
phere. Murine D1 MSCs engineered to secrete erythropoietin
(D1-MSCs-EPO) (Gurruchaga et al., 2015) were grown with
DMEM (Gibco) supplemented with 10% FBS (Gibco) and 1%
penicillin/streptomycin solution (Gibco) at 37 C in humidified
5% CO2 atmosphere. Cells were passaged every 2–3 d.
Cell encapsulation
Sterile 1.5% and 1.87% alginate solutions were prepared by
dissolving LVG alginate in 1% mannitol solution and filtered
through a 0.20-mM syringe filter (Millipore, Billerica, MA, USA).
GO was suspended in FBS (Gibco) at a concentration of
250mg/ml and sonicated for 1 h. GO suspensions were mixed
with 1.87% alginate solutions to a final concentration of 1.5%
alginate and the following GO final concentrations: 50 mg/ml,
25 mg/ml, and 10 mg/ml. Murine C2C12-EPO cells and D1-MSCs-
EPO cells were harvested using 0.25% trypsin-EDTA (Life
Technologies, Carlsbad, CA, USA) and re-suspended into the
sterile 1.5% alginate solutions containing 50 mg/ml, 25 mg/ml,
or 10 mg/ml GO. As controls, C2C12-EPO cells and D1-MSCs-EPO
cells were resuspended in a 1.5% alginate solution without
GO. Cells were encapsulated at a density of 5 106 cells/ml of
alginate. Suspensions were extruded using a 5ml sterile syr-
inge through a disposable nebulizer in a pneumatic atomiza-
tion generator (Bioencapsulation portable platform CellenaVR )
or an electrostatic atomization generator (NiscoVR ). The result-
ing alginate beads were maintained in agitation for 10min in
a CaCl2 solution (55mM) for complete ionic gelation.
Afterwards, they were ionically linked with 0.05% (w/v) PLL for
5min and coated with 0.1% LVG alginate for another 5min.
Microcapsules were prepared at room temperature, under
aseptic conditions and were cultured in C2C12-EPO and D1-
MSCs-EPO media. The diameters (160 mm and 380 mm) and
overall morphology of microcapsules were characterized using
an inverted optical microscopy (Nikon TSM).
Early apoptosis quantification
Early apoptosis of microencapsulated C2C12-EPO and
D1-MSCs-EPO cells with alginate and 50 mg/ml, 25 mg/ml, and
10 mg/ml concentrations of GO was quantified with the
Annexin-V-FITC Apoptosis Detection Kit (Sigma-Aldrich) at
days 1 and 7 post-encapsulation. Microencapsulated cells in
alginate matrices without GO were studied as controls.
Briefly, 200 ml of microcapsules (106 cells) were incubated
with alginate lyase (Sigma-Aldrich) for 30min at 37 C to
release the cells. The lysate was rinsed twice with DPBS and
re-suspended in binding buffer consisting of 10mM HEPES/
NaOH, pH 7.5, containing 0.14M NaCl and 2.5mM CaCl2
(binding buffer) and stained with annexin V-FITC and propi-
dium iodide for 10min at room temperature protected from
light. Unstained samples or stained only with annexin V-FITC
or propidium iodide were used to establish the appropriate
acquisition parameters for the analyzed samples. Fluorescence
was determined in a BD FACS Calibur flow cytometer. Three
independent samples were analyzed for each condition.
Cell viability
Cell viability of microencapsulated cells in alginate matrices
with 50 mg/ml, 25 mg/ml, and 10 mg/ml concentrations of GO
was quantified with the LIVE/DEADVR Viability/Cytotoxicity
Kit (InvitrogenTM) at days 1 and 7 post-encapsulation.
Encapsulated cells in alginate without GO were studied as
controls. Cells were released from microcapsules by incuba-
tion with alginate lyase for 30min at 37 C, and stained with
100 nM calcein AM and 8mM ethidium homodimer-1 solution
for 20min at room temperature, protected from light.
Unstained samples or stained only with 100 nM calcein AM
or 8 mM ethidium homodimer-1 were ran as controls to
establish the appropriate acquisition parameters for the ana-
lyzed samples. Fluorescence was quantified in a BD FACS
Calibur flow cytometer. Three independent samples were
analyzed for each condition.
For microscopy imaging, a volume of 25 mL of microencap-
sulated cells was rinsed twice in DPBS and re-suspended in
500 mL of 0.5 lM calcein AM and 0.5 lM ethidium homo-
dimer-1 in DPBS. Next, solutions were placed in a 96-well
plate and incubated at room temperature protected from
light for 45min. Samples were observed under a Nikon TMS
confocal microscope at the wavelength of excitation 495 nm/
emission 515 nm (for calcein AM staining) and excitation
495 nm/emission 635 nm (for ethidium homodimer staining).
Random images were analyzed with the Eclipse Net software,
version 1.20.0.
Metabolic activity assay
Encapsulated cell metabolic activity was quantified at day 1
and 7 post-encapsulation. Five microliters per well of each
encapsulated cell type were placed in 100 ml of medium on
96-well plates. Encapsulated cells in alginate without GO
were used as controls. At least six wells were placed for each
condition. Afterwards, 10 ml of Cell Counting Kit-8 CCK-8 solu-
tion (Sigma Aldrich) were added to each well. Plates were
incubated inside a humidified chamber for 4 h at 37 C and
read on an Infinite M200 TECAN microplate reader at 450 nm
with reference wavelength at 650 nm. At least three
independent experiments were analyzed for each GO
concentration.
Toxicology assay based on lactic dehydrogenase
(LDH) detection
The membrane integrity of encapsulated cells was quantified
with the in vitro toxicology assay kit, LDH based (Sigma-
Aldrich) 1 and 7 d after encapsulation. A total of 500ml of
medium was incubated with 50 ml of each type of encapsu-
lated cells for 24 h, and 50 ml of supernatants were collected
to determine LDH release activity. At the same time, 50 ml of
each encapsulated cell type were incubated for 24 h with
500 ml of medium and lysed to determine the total LDH activ-
ity. All collected media were subjected to reaction with tetra-
zolium dye following manufacturer's recommendations. The
resulting colored compound absorbance was read out on an
Infinite M200 TECAN microplate reader at a wavelength of
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490 nm, reading at 690 nm absorbance as background. At
least three independent experiments were analyzed for each
GO concentration.
EPO and VEGF quantification
The secretion of EPO and VEGF for 24 h was quantified from
each encapsulated D1-MSCs-EPO cell condition, 1 and 7 d
after cell encapsulation. From encapsulated C2C12-EPO cells,
only EPO secretion was quantified following the same pro-
cedure. A volume of 100mL of microcapsules were rinsed
twice with culture medium, re-suspended in 1mL of medium
and incubated for 24 h at 37 C and 5% CO2. Then, superna-
tants were collected. Next microcapsules were cultured for
7 d, changing medium every 2 d, and rinsing twice 24 h
before collecting supernatant at the end of the culture. The
EPO secretion from the supernatants was quantified by
Quantikine IVD EPO ELISA kit (R&D Systems, Minneapolis, MN,
USA) while the secretion of VEGF was quantified by Human
VEGF Standard ABTS ELISA Development Kit (Peprotech,
London, UK) following manufacturer recommendations. Three
independent samples and controls for each condition
were assayed.
Implantation and retrieval of encapsulated cells
Six weeks old allogenic Balb/c and C3H mice were purchased
from Janvier Labs (Le Genest-Saint-Isle, France) and housed
with sterile feed and autoclaved water. The following four
different groups of alginate microcapsules containing C2C12-
EPO cells or D1-MSCs-EPO cells were produced and
implanted into 6 weeks old Balb/c or C3H mice, respectively:
380mm diameter alginate microcapsules, 380mm diameter
alginate microcapsules containing 50 mg/ml of protein
coated-GO, 160mm diameter alginate microcapsules and
160mm diameter alginate microcapsules containing 50 mg/ml
of protein coated-GO. All the microcapsules were manufac-
tured 1 d before implantation. Five animals per group were
implanted subcutaneously with 200ml of the respective
encapsulated cells suspended in Hanks Balanced Salt
Solution in a final volume of 1ml using a 18-gauge catheter.
During the procedure, all animals were maintained under
anesthesia by isofluorane inhalation. Blood samples were col-
lected weekly by facial vein puncture with heparinized capil-
lary tubes (Deltalab, Barcelona, Spain), and capillaries were
spun down at 760 g for 15min. Hematocrits were deter-
mined using a standard microhematocrit method and
expressed as mean± standard deviation. Animals were sacri-
ficed 6weeks after implantation and the foreign body capsu-
les containing microcapsules were retrieved. All the
experimental procedures were performed in compliance with
protocols approved by the institutional animal care and use
committee of the University of Basque Country UPV/EHU
(Permit Number: CEEA/360/2014/CIRIZA ASTRAIN).
The retrieved fibrotic capsules containing microcapsules
from at least 3 implanted mice with each type of encapsu-
lated cells were disaggregated by incubation at 37 C for
3–4 h with sterile 2mg/ml collagenase H and 1mg/ml
hyaluronidase dissolved in DMEM. The disaggregated suspen-
sion was filtered through a 70-mm strainers into a 50ml con-
ical tube, collecting microencapsulated cells on the top of
the strainers and the solution containing the infiltrated cells
from the fibrotic capsules in the conical tube. Next, infiltrated
cells were collected by spinning down the disaggregated fil-
tered solution, storing supernatant for further analysis, and
re-suspending the pellet with medium into a single cell
suspension for flow cytometry analysis.
Metabolic activity and cell viability of retrieved
encapsulated cells
Metabolic activity was quantified from 25 ml of each retrieved
microencapsulated cell sample with the Cell Counting Kit-8
CCK-8 (Sigma Aldrich), following the same procedure
described above. For cell viability, 25 ml of each retrieved
microencapsulated cell type were rinsed twice in DPBS and
stained with calcein AM and ethidium homodimer-1 as previ-
ously described.
FACS analysis
For flow cytometry analysis, freshly single cell suspensions
from solutions containing the infiltrated cells from the
fibrotic capsules were stained with anti-CD16/32 antibody to
block FccII/III receptors. Fc blockage was followed by a
15-min staining with either an antibody cocktail containing
PE-Cy7-conjugated anti-CD45, FITC-conjugated anti-CD3,
PE-conjugated anti-CD4 and APC-conjugated anti-CD8 or the
cocktail containing APC-conjugated anti-CD11b, PE-conju-
gated anti-CD19, APC-Cy7-conjugated anti-NK1.1and
PE-Cy7-conjugated anti-CD45. After rinsing, DAPI (6 mM final
concentration) was added before analysis to exclude dead
cells. At least 106 cells/sample were analyzed using a
MACSQuant Analyzer 10 flow cytometer controlled by
MACSQuantifyTM Software’s (Miltenyi Biotec S.L., Bergisch
Gladbach, Germany). Unstained cells were used to evaluate
autofluorescence while fluorescent minus one controls were
used to determine gates. Each experiment was carefully com-
pensated by single staining single suspensions with the
appropriate antibody: fluorochrome combination. In all
cytometry experiments, at least three samples were analyzed
for each condition.
MagPix
Cytokines were assayed using a Luminex Magpix-based assay
(Luminex Corporation, Austin, TX). Twenty-three cytokines
(Eotaxin, G-CSF, GM-CSF, IFN-c, IL-1a, IL-1b, IL-2, IL-3, IL-4, IL-5,
IL-6, IL-9, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-17A, KC, MCP-1
(MCAF), MIP-1a, MIP-1b, RANTES, and TNF-a) from the Bio-Plex
ProT Mouse Cytokine 23-plex Assay (Bio-Rad, Hercules, CA,
USA) were analyzed. The supernatant collected from at least
three disaggregated retrieved fibrotic capsules containing
microcapsules were thawed at 4 C, centrifuged at 1400 g to
remove any aggregate protein that may potentially obstruct
the measurement and transferred to a fresh tube. An 8-point
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standard curve with serial dilutions of 1:4 was generated using
reconstituted stock standards supplied by the manufacturer;
quality controls supplied by the manufacturer were also used
to determine assay accuracy. The data were generated using
the Bio-Plex Manager Software (Bio-Rad, Hercules, CA, USA). All
samples were assayed in duplicate. The average coefficient of
variance for duplicate values across analytes for samples was
5%. The average minimum detectable value across all plates
was 0.56 pg/ml for IL-1a, 2.07 pg/ml for IL-1b, 0.98 pg/ml for IL-
2, 0.46 pg/ml for IL-3, 0.4 pg/ml forIL-4, 0.79 pg/ml for IL-5,
0.7 pg/ml for IL-6, 2.4 pg/ml for IL-9, 3.77 pg/ml for IL-10,
8.33 pg/ml forIL-12(p40), 20.22 pg/ml for IL-12(p70), 11.11 pg/
ml for IL-13, 0.41 pg/ml for IL-17A, 7.9 pg/ml for Eotaxin,
3.78 pg/ml for G-CSF, 4.44 pg/ml for GM-CSF, 0.8 pg/ml for IFN-
c, 1.22 pg/ml for KC, 45.33 pg/ml for MCP-1,0.44 pg/ml for MIP-
1a, 3.14 pg/ml for MIP-1b, 1.91 pg/ml for RANTES and 4.44 pg/
ml for TNF-a.
Immunohistochemistry
The retrieved fibrotic capsules containing microcapsules were
included in OCT (VWR chemicals, Radnor, PA, USA), frozen
and kept at 80 C until their study. About 10 mm cryosec-
tions were cut and stained with hematoxylin and eosin and
Masson’s trichrome. Microscopy sections were examined by a
pathologist/expert blinded to the treatments. The presence
and distribution of infiltrating cells, preservation, and vascu-
larization of the tissue along with the extension of fibrosis
were evaluated.
Statistical analysis
Statistical analysis was performed using SPSS software, ver-
sion 21.00.1, or GraphPad Prism 5.01 (GraphPad Inc., San
Diego, CA, USA). Data are expressed as a mean± standard
deviation. Values from p< .05 to p< .001 were considered
significant for comparison of groups using ANOVA, Tukey’s
post hoc test or Kruskal–Wallis H test.
Results and discussion
Doubling diameter of hybrid alginate-protein-coated GO
microcapsules enhances encapsulated myoblasts
viability and protein release
First, we aimed to study the behavior of encapsulated genet-
ically modified C2C12 myoblasts within hybrid alginate-pro-
tein-coated GO microcapsules (hybrid microcapsules) with
diameters higher than 300 mm, trying to determine if an
increment in size would affect the benefits observed with
160mm diameter hybrid microcapsules (Saenz Del Burgo
et al., 2017). We compared viability, metabolic activity, cell
membrane integrity and protein release of encapsulated
C2C12-EPO cells in 160 and 380 mm diameter hybrid microcap-
sules, performed in a pneumatic (Bioencapsulation portable
platform CellenaVR ) and an electrostatic (NiscoVR ) atomization
generator, respectively (Supplementary Figure 1). We gener-
ated both diameter hybrid microcapsules at a concentration
of 50 mg/ml of GO, comparing them with microcapsules with-
out GO, since this GO concentration within alginate micro-
capsules has previously shown to be the optimal
concentration for myoblasts survival enhancement (Ciriza
et al., 2015). All hybrid microcapsules presented a homogen-
ous spherical shape.
Next day and 7 d after encapsulation, we quantified signifi-
cantly lower apoptotic cell population (p< .05 and p< .001,
respectively) in presence of GO with both diameters of micro-
capsules, compared to their counterparts without GO.
Although we confirmed apoptosis reduction both days after
encapsulation caused by the presence of protein-coated GO
within 160 mm diameter microcapsules (Saenz Del Burgo et al.,
2017), significant higher apoptotic cell percentage reduction
(p< .001) was quantified with 380 mm diameter hybrid micro-
capsules 7 d after encapsulation (Figure 1(A)). These results
indicated that the presence of protein-coated GO in 380 mm
diameter microcapsules improves the beneficial effect
detected in smaller microcapsules. Viability quantification
assays reinforced apoptosis results (Figure 1(B)). Both diame-
ters of GO coated encapsulated C2C12-EPO cells showed sig-
nificantly lower dead cell percentage (p< .001) the next day
and 7 d after encapsulation, compared with their counterparts
without GO. However, the reduction in dead cell percentage
was significantly higher in 380 mm diameter microcapsules
than in 160 mm (p< .001), confirming again the beneficial
improvement of the combination of protein-coated GO and
bigger diameter microcapsules. These results were verified
under fluorescent microscope after staining encapsulated cells
with calcein/ethidium (Figure 1(C)), confirming that the pres-
ence of protein-coated GO reduces apoptosis and cell death
in alginate microcapsules with a more accused effect in
380 mm diameter microcapsules.
Metabolic activity quantification also confirmed the bene-
ficial effect of the presence of GO nanoparticles. Similarly to
160 mm diameter hybrid microcapsules (Saenz Del Burgo
et al., 2017), metabolic activity of encapsulated C2C12-EPO
myoblasts within 380 mm diameter hybrid microcapsules was
significantly higher (p< .05) than their counterparts without
GO (Figure 2(A)). However, the analysis of cell membrane
integrity showed that the presence of protein-coated GO
nanoparticles affected the encapsulated C2C12-EPO myoblasts
membrane integrity (Figure 2(B)). When cell membrane is
damaged, intracellular LDH is released into the medium,
and therefore LDH levels reflect the integrity of the cell
membrane. The significant detected increment (p< .001) in
LDH leakage compared to microcapsules without GO, and
therefore, the worse cell membrane integrity, suggest that
protein-coated GO nanoparticles could provoke some toxicity
to encapsulated C2C12-EPO myoblasts within 380 mm diam-
eter-hybrid alginate- GO microcapsules, similar to the results
previously described with graphene and single-wall carbon
nanotubes (Zhang et al., 2010). However, like microcapsules
without GO, LDH release decreased over time, with lower
LDH release 7 d after encapsulation, indicating that any toxic
effect of protein-coated GO nanoparticles within the micro-
capsules is overcome over time.
Finally, we quantified the release of the therapeutic agent
EPO by encapsulated cells because the sustained drug
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delivery is one of the main advantages for preclinical applica-
tions offered by this encapsulation technology (Orive et al.,
2005; Murua et al., 2009). We studied and compared the
release of EPO produced by encapsulated C2C12-EPO myo-
blasts in the presence and absence of protein-coated GO
nanoparticles. Both hybrid microcapsules showed a signifi-
cant increment (p< .001) in EPO production and release com-
pared to microcapsules without GO (Figure 2(C)). Since the
presence of FBS-coated GO reduces the number of dead and
apoptotic cells (Figure 1(A,B)), it can be concluded that the
higher EPO release quantified is a consequence of an incre-
ment in the number of viable cells. Moreover, significant
higher release was detected in C2C12-EPO myoblasts within
380mm diameter hybrid microcapsules than in 160mm at day
7 (p< .05), concluding that doubling hybrid alginate-protein-
coated GO microcapsules size enhances encapsulated myo-
blasts sustained release in vitro.
Viability of encapsulated MSCs within hybrid alginate-
protein-coated GO microcapsules is also enhanced
Next, we studied the behavior of encapsulated MSCs within
380mm and 160 mm diameter hybrid microcapsules before
performing in vivo implantations, with the goal of further cir-
cumvent the in vivo immune rejection of hybrid alginate-GO
encapsulated cells through the immune-modulation from
MSCs of the microenvironment (Maccario et al., 2005;
Meirelles Lda et al., 2009; Shi et al., 2011; Gebler et al., 2012).
So, first, we studied the biocompatibility of different GO con-
centrations up to 50 mg/ml, which are required in alginate-
GO cell microencapsulation for each cell type and therapeutic
protein (Ciriza et al., 2015), since concentrations higher than
50 mg/ml difficult the manufacturing in the encapsulator devi-
ces. Thus, we produced encapsulated D1-MSCs-EPO cells in
160 and 380mm diameter hybrid microcapsules with the
pneumatic and the electrostatic atomization generator,
respectively, at 10, 25, and 50 mg/ml of GO concentrations
and 5 106 cells/ml cell density to, next, compare their via-
bility, metabolic activity, cell membrane integrity, and protein
release with alginate microcapsules without GO. All hybrid
microcapsules generated displayed spherical shape. We quan-
tified lower apoptosis in 160 mm diameter microcapsules than
in 380 mm, independently of the protein-coated GO presence
or absence (Figure 3(A)). However, when comparing 380 mm
diameter hybrid microcapsules with their counterpart without
GO, the decrease in percentage of apoptotic cells was signifi-
cantly higher (p< .001), than when comparing 160 mm diam-
eter hybrid alginate- GO microcapsules with their counterpart
without GO. These results indicate that the presence of pro-
tein-coated GO nanoparticles helps to reduce apoptotic
Figure 1. Viability of encapsulated C2C12-EPO myoblasts within 160 and 380mm diameter alginate (0 mg/ml) and hybrid alginate-GO microcapsules (50mg/ml),
1 and 7 d after microencapsulation: (A) Fold reduction of apoptotic cell percentage compared to microcapsules without GO quantified by flow cytometry of early
apoptosis by means of annexin/PI staining and (B) Fold reduction of dead cell percentage compared to microcapsules without GO quantified by flow cytometry
after calcein/ethidium staining. (C) Fluorescence and bright field microscopy images after calcein/ethidium staining. Scale bar 100 mm. Note p< .05, p< .01, andp< .001 compared with cells encapsulated in alginate without GO.
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processes. It is remarkable that similarly to encapsulated
C2C12-EPO myoblasts (Saenz Del Burgo et al., 2017), and inde-
pendently of the microcapsule diameter, protein-coated GO
nanoparticles at 50 mg/ml was the concentration with the
lowest apoptotic cell percentage. Viability quantification
assays provided similar results than apoptosis. Both diameters
of encapsulated D1-MSCs-EPO cells showed significantly
lower death cell percentage (p< .001) than their counterparts
without GO (Figure 3(B)), but the reduction in death cell per-
centage was also higher in 380 mm diameter microcapsules
than in 160 mm, reinforcing the higher beneficial effect of the
combination of protein-coated GO and 380 mm diameter
microcapsules instead of 160 mm. Again, and similarly to
encapsulated C2C12-EPO myoblasts (Saenz Del Burgo et al.,
2017), protein-coated GO nanoparticles at 50 mg/ml showed
the lowest dead cell percentage, independently of the micro-
capsule diameter. Micrographs displayed after staining encap-
sulated cells with calcein/ethidium confirmed these results
(Figure 3(C)), and indicated that 50 mg/ml protein-coated GO
reduces optimally apoptosis and cell death in alginate micro-
capsules, with an accused effect in 380 mm diameter
microcapsules.
Metabolic activity was also significantly higher for all the
encapsulated D1-MSCs-EPO cells in hybrid microcapsules
compared to their counterparts without GO, independently
of the diameter studied (Figure 4(A)) and similarly to encap-
sulated C2C12-EPO myoblasts (Ciriza et al., 2015; Saenz Del
Burgo et al., 2017). However, different results were observed
comparing the metabolic activity among the different pro-
tein-coated GO concentrations at both microcapsules diame-
ters. In 160 mm diameter hybrid microcapsules, 10 mg/ml
protein-coated GO provided no significant higher values of
metabolic activity 7 d after encapsulation (Figure 4(A)).
However, in 380 mm diameter hybrid microcapsules 25 mg/ml
protein-coated GO provided the highest values of metabolic
activity since the first day after encapsulation. In spite of
these differences, all metabolic activities were higher than
observed with microcapsules without GO (Figure 4(A)), con-
firming again the benefits of protein-coated GO nanopar-
ticles. Similar results were shown when the membrane
integrity was analyzed. Encapsulated D1-MSCs-EPO within
both diameters of hybrid microcapsules displayed better
membrane integrity than their counterparts without GO the
first day after encapsulation, independently of the protein-
coated GO concentration studied reaching similar membrane
integrity values 7 d after encapsulation (Figure 4(B)). The
beneficial effects observed from GO could be related to two
factors. On one hand, the protective effect previously
described by GO in 3D matrixes (Ciriza et al., 2015). On the
other hand, since GO is able to adsorb the 25% of the serum
Figure 2. (A) Metabolic activity and (B) cell membrane integrity of encapsulated C2C12-EPO myoblasts within 380mm diameter alginate and hybrid alginate-GO
microcapsules (50 mg/ml), 1 and 7 d after microencapsulation. (C) EPO secretion 1 and 7 d after microencapsulation of C2C12-EPO myoblasts within 160 and 380 mm
diameter alginate and hybrid alginate-GO microcapsules (50mg/ml). Note p< .05, p< .01, and p< .001 compared with cells encapsulated in alginate with-
out GO.
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proteins, such as some extracellular matrix globular proteins
and glycoproteins like fibronectin (Cedervall et al., 2007;
Dell'Orco et al., 2010; Lee et al., 2011; Saenz Del Burgo et al.,
2017), FBS coating could enhance GO protective effect by
facilitating cell adhesion, similarly to the RGD (motif from
fibronectin) modified alginates (Orive et al., 2009, Garate
et al., 2015).
D1-MSCs-EPO cells are genetically engineered to secrete
EPO (Gurruchaga et al., 2015). Thus, we quantified the sus-
tained drug delivery of this therapeutic agent in the hybrid
microcapsules. Cells encapsulated within hybrid microcapsules
at both diameters released significantly higher (p< .001)
amount of the therapeutic protein than alginate microcap-
sules without GO 7d after encapsulation (Figure 4(C)), similarly
Figure 3. Viability of encapsulated D1-MSCs EPO within 160 and 380 mm diameter alginate and hybrid alginate-GO microcapsules (10, 25, and 50 mg/ml), 1 and 7 d
after microencapsulation: (A) Quantification by flow cytometry of early apoptosis by means of annexin/PI staining and (B) live/dead percentage by means of
calcein/ethidium staining. (C) Fluorescence microscopy images after calcein/ethidium staining. Scale bar 100 mm. Note p< .001 compared with cells encapsu-
lated in alginate without GO.
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to encapsulated C2C12-EPO myoblasts (Ciriza et al., 2015; Saenz
Del Burgo et al., 2017). Moreover, doubling the hybrid micro-
capsules size also enhanced the release of the therapeutic pro-
tein synthesized by the encapsulated MSCs in vitro.
Interestingly, 380 mm diameter hybrid alginate-GO microcap-
sules containing 50 mg/ml protein-coated GO released no sig-
nificant higher amount of EPO overtime, while 160 mm
diameter hybrid microcapsules containing 25 mg/ml protein-
coated GO released more amount of EPO overtime (Figure
4(C)). However, no significant differences were detected
among the different GO concentrations in both diameter
hybrid microcapsules. Because the presence of protein-coated
GO nanoparticles in alginate microcapsules could also be influ-
encing the release of endogenous proteins secreted by MSCs,
we also compared the endogenous release of VEGF
(Beckermann et al., 2008). Hybrid microcapsules released sig-
nificantly more VEGF (p< .05) than alginate microcapsules
without GO, independently of the GO nanoparticles concen-
tration within both microcapsule diameters (Figure 4(D)). This
increment of VEGF release was correlated with the increment
of EPO secretion, indicating that the secretion enhancement
could be influenced by the boost of metabolic activity through
GO, similarly to alginate microcapsules containing hyaluronic
acid (Canibano-Hernandez et al., 2017).
Figure 4. (A) Metabolic activity and (B) cell membrane integrity of encapsulated D1-MSCs EPO within 160 mm (left) and 380 mm (right) diameter alginate and hybrid
alginate-GO microcapsules (10, 25, and 50 mg/ml), 1 and 7 d after microencapsulation. (C) EPO and (D) VEGF secretion 1 and 7 d after microencapsulation of
D1-MSCs EPO within 160 and 380 mm diameter alginate and hybrid alginate-GO microcapsules (10, 25, and 50 mg/ml). Note p< .05, p< .01, and p< .001
compared with cells encapsulated in alginate without GO.
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Doubling the diameter of hybrid alginate-protein-coated
GO microcapsules enhances EPO release by
encapsulated cells in vivo
After observing the increment of EPO release in either encap-
sulated C2C12-EPO myoblasts or D1-MSCs-EPO within 160 or
380mm diameter hybrid microcapsules, we wonder if the
EPO release increment quantified in both encapsulated cell
types and hybrid microcapsules diameters would be reflected
in murine hematocrit levels after microcapsules implantation.
We implanted, therefore, 200 ml of encapsulated C2C12-EPO
myoblasts or D1-MSCs-EPO within 160 and 380 mm diameter
hybrid (50mg/ml) microcapsules into allogeneic Balb/c and
C3H mice, respectively, and determined their blood hemato-
crit levels for 6weeks, comparing with mice implanted with
the respective microcapsule without GO. Three weeks after
implantation, the hematocrit significantly (p< .001) increased
in allogeneic mice implanted with encapsulated cells within
380mm diameter hybrid alginate- GO microcapsules
(Figure 5(A)). Mice implanted with both encapsulated cell
types within 160mm diameter hybrid microcapsules did not
significantly increase hematocrit blood levels compared to
their counterparts without GO, in contrast to expected from
EPO release in vitro results or the significant hematocrit
blood level increment described after implantation of encap-
sulated C2C12-EPO myoblasts within 160 diameter hybrid
microcapsules into syngeneic mice (Saenz Del Burgo et al.,
2017). We also quantified the metabolic activity of the
retrieved microcapsules 6weeks after implantation. Similarly
to in vitro studies with encapsulated C2C12-EPO myoblasts
(Figure 2(A)) and D1-MSCs-EPO (Figure 4(A)) within 380 mm
diameter hybrid microcapsules, retrieved hybrid microcap-
sules showed significantly higher metabolic activity (p< .005)
than their counterparts without GO (Figure 5(B)). However,
retrieved encapsulated cells within 160 mm diameter hybrid
microcapsules displayed reduced metabolic activity than their
counterparts without GO, with more significant pronounced
effect (p< .001) in hybrid microcapsules containing C2C12-
EPO myoblasts than those containing D1-MSCsEPO (Figure
5(B)). These results of metabolic activity were corroborated
by microscopy images obtained after calcein/ethidium stain-
ing (Figure 5(C)), indicating that 160 mm diameter hybrid
microcapsules do not behave similarly to in vitro conditions.
This lower metabolic activity of 160mm diameter hybrid
microcapsules would explain the lack of significant increment
in the hematocrit of implanted allogeneic mice when com-
pared to mice implanted with the controls without GO. In
fact, one of the major challenges in the use of allogeneic
cells is their potential transplant rejection (Li & Duncan, 1998;
Tambuyzer et al., 2009). The hematocrit of syngeneic recipi-
ents implanted with no encapsulated MSCs engineered to
release murine EPO rapidly rises from baseline level, remain-
ing high for more than 200 d, while in MHC-mismatched
recipient mice, the hematocrit transiently rises, rapidly
declining to baseline values (Eliopoulos et al., 2005).
Allogeneic non encapsulated MSC implants shows increased
infiltration of CD8 and NK cells compared to syngeneic con-
trols, with a significant interferon-gamma response in the
spleens (Eliopoulos et al., 2005). So, we hypothesized that
although 500 mm diameter alginate microcapsules loaded
with C2C12-EPO myoblasts and subcutaneously implanted in
allogeneic mice are able to maintain high and constant hem-
atocrit levels for more than 100 d (Orive et al., 2005), immune
system could affect more to smaller microcapsules, with
diameters of 160 mm, creating a similar scenario to the afore-
mentioned allogeneic implantation of MSCs secreting EPO
(Eliopoulos et al., 2005).
Modifying the diameter of hybrid alginate-protein-
coated GO microcapsules does not affect foreign
body reaction
Recent studies have shown that tuning spherical dimensions
improves the biocompatibility of biomedical devices, demon-
strating that a three-fold increment of alginate capsules pro-
longs the period of blood glucose restoration in
streptozotocin-treated diabetic C57BL/6 mice five times lon-
ger by mitigating foreign reactions and fibrosis (Veiseh et al.,
2015). We studied, therefore, if the microcapsule size, the
presence of protein-coated GO (50 mg/ml) within the micro-
capsules or the cell type within the microcapsules could
induce a stronger immune response after allogeneic implant-
ation. We easily recovered in one piece the explanted grafts
from MHC-mismatched mice 6weeks after implantation of
either encapsulated C2C12-EPO myoblasts or D1-MSCs-EPO
within 160 or 380 mm diameter hybrid microcapsules. The
microcapsule network from all the groups was surrounded
by blood capillaries showing a weak fibrotic layer surround-
ing the APA microcapsules in the histological analyses.
Histological evaluation of the explanted microcapsules evi-
denced the formation of pericapsular overgrowth maybe due
to the direct contact of the pro-inflammatory PLL at the sur-
face of APA microcapsules with cells of the host immune
response (Tam et al., 2005, 2011). Hematoxylin-eosin staining
evidenced the presence of erythrocytes in all the grafts with
higher preponderance in samples from allogeneic animals
implanted with microcapsules containing GO (Figure 6(A)),
with the exception of 160 mm diameter hybrid microcapsules
containing D1-MSCs-EPO and in accordance with the hem-
atocrit increment observed (Figure 5(A)). Moreover, samples
with higher presence of erythrocytes were accompanied by
higher vascularization, confirming that the presence of GO in
hybrid microcapsules improves the release of EPO in vivo.
Masson’s trichrome staining showed fibrotic tissue in all the
samples implanted without differences visualized among the
different grafts, independently of the microcapsules
implanted (Figure 5(B)). Fibrin staining could be detected in
grafts from implantations with encapsulated C2C12-EPO myo-
blasts, indicating that D1-MSCs-EPO could slightly attenuate
the initiation of the foreign body reaction compared to
encapsulated C2C12-EPO myoblasts. However, the data indi-
cate that the inclusion of FBS coated GO does not provoke a
significant modification in the immune reaction compared to
the immune reaction induced by alginate microcapsules
without GO.
Next, we quantified the protein expression of 23 inflam-
mation-related cytokines within the supernatant collected
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from at all the retrieved grafts containing microcapsules
(Figure 6(C)). No significant differences were detected in the
expression of all the cytokines among all the explanted
grafts. However, higher expression of pro-inflammatory cyto-
kines was detected in grafts from encapsulated C2C12-EPO
myoblasts compared to encapsulated D1-MSCs-EPO
implanted allogeneic mice, especially when comparing GO
containing counterparts. These results would suggest slight
immune response attenuation in the surrounding environ-
ment by encapsulated D1-MSCs-EPO in terms of pro-inflam-
matory cytokines secretion.
We also quantified in all the retrieved grafts the percent-
age of the following infiltrated cell populations by flow
cytometry: CD45þCD3þCD4þCD8-, CD45þCD3þCD4-CD8þ,
CD11bþ, CD19þ, and NK1.1þ. No significant differences in
the percentage of any of the infiltrated cell population
studied were detected among the samples retrieved from
mice (data not shown), indicating that the studied immune
cell populations do not significantly affect microcapsules
with different size or with GO. Although the host response
kinetic profile 1 month after subcutaneous or intraperitoneal
implantation have previously shown a reduced significant
Figure 5. Subcutaneous allogenic implantation of encapsulated C2C12-EPO myoblasts and D1-MSCs EPO within 160 and 380 mm diameter alginate and hybrid
alginate-GO microcapsules (50 mg/ml). (A) Hematocrit levels in C3H (left) and Balb/c (right) mice expressed as meanþ SD after allogenic implantation. (B) Metabolic
activity of retrieved encapsulated C2C12-EPO myoblasts from C3H mice (left) and encapsulated D1-MSCs EPO from Balb/c mice (right). (C) Fluorescence microscopy
images after calcein/ethidium staining of the retrieved encapsulated cells. Scale bar 200mm. Note p< .01 and p< .001 compared with cells encapsulated in
alginate without GO.
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percentage of macrophages and neutrophils in 1.5mm
implanted spherical capsules compared to 0.5mm capsules
(Veiseh et al., 2015), we did not detect significant immune
cell population differences after implantation by tuning our
microcapsules size to higher diameters. This lack of
differences could reside in the different capsule sizes studied,
since our microcapsules range 160–380 mm, instead of
0.5–1.5mm, which could give rise to different host response
kinetic profile. Moreover, the studied host strains, Balb/c and
C3H, could also provoke different host response kinetic
Figure 6. Foreign body reaction analysis 6 weeks after subcutaneous allogenic implantation of encapsulated C2C12-EPO myoblasts and D1-MSCs EPO within 160
and 380mm diameter alginate and hybrid alginate-GO microcapsules (50 mg/ml). (A) Representative photographic images of hematoxylin-eosin staining of explanted
grafts after 6 weeks (B) Representative photographic images of Masson's trichrome staining of explanted grafts after 6 weeks (C) Expression analysis of 23 inflamma-
tion-related cytokines by means of Bio-Plex Pro Mouse Cytokine 23-Plex Immunoassay. Flow cytometry quantification of D) CD11b and (E) CD19 percentage infil-
trated cells from the retrieved fibrotic capsules. Note: Scale bar 100 mm.
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profile compared to the previously described implanted
C57BL/6 mouse strain, which produces stronger fibrotic and
foreign body response (Kolb et al., 2002). Another factor that
could modify the host kinetic profile is the presence of con-
taminating endotoxins, which induce stronger foreign body
reaction (Paredes-Juarez et al., 2013). Finally, the protein
release profile from different cell types could also influence
the immune response, with different host response against
encapsulated rat islets (Veiseh et al., 2015) than encapsulated
myoblasts or MSCs. In fact, MSCs are able to immune-modu-
late the microenvironment by inhibiting the function of dif-
ferent immune cell subpopulations of the innate and
adaptive immunity (Shi et al., 2011), e.g. suppressing T cell
proliferation through the secretion of PGE-2, IDO, and TGF-b
(Meirelles Lda et al., 2009), inducing
CD4þCD25þ FoxP3þ and CD8þ regulatory cells (Maccario
et al., 2005), blocking B cells proliferation in presence of
IFN-c (Gebler et al., 2012) and down-regulating the co-
stimulatory molecules CD40, CD80, and CD86 expression on
dendritic cells (Nauta et al., 2006). Interestingly, we detected
lower CD11bþ and CD19þ infiltrated cell percentage in mice
implanted with encapsulated D1-MSCs-EPO than with C2C12-
EPO myoblasts. These not significant differences were inde-
pendent of the capsule diameter or the presence/absence of
protein coated-GO nanoparticles (Figure 6(D–E)) suggesting
that MSCs can modulate the essential innate (macrophage)
and adaptative (B cell) immune population in the fibrotic
response to implanted alginate microcapsules (Doloff et al.,
2017). Stronger fibrotic and foreign body response from dif-
ferent murine strains, such as C57BL/6 (Kolb et al., 2002)
could have provided a more accused significant percentage
reduction of CD11bþ and CD19þ infiltrated cell after allogen-
eic implantation. We believe that the combination of new
hydrogel surfaces (Vegas et al., 2016) and encapsulated MSCs
could mitigate the foreign body response without the need
of immune suppression regimes, or the specific blockade or
inhibition of chemokines and/or cytokines involved in the
recognition and propagation of foreign body rejection
response to hydrogels (Doloff et al., 2017).
Conclusions
We have corroborated that the presence of 50 mg/ml protein-
coated GO nanoparticles within alginate microcapsules
reduces apoptosis and increase cell survival, metabolic activ-
ity, and therapeutic protein release of encapsulated myo-
blasts and MSCs. Moreover, we have demonstrated that a
two-fold size increment of alginate microcapsules diameter
enhances even more the beneficial effects created by the
presence of GO within microcapsules. Importantly, this sig-
nificant improvement of therapeutic protein release in
hybrid alginate-protein-coated GO microcapsules is directly
translated in vivo, providing a quicker and higher physio-
logical outcome.
Interestingly, the encapsulation of MSCs suggests a reduc-
tion of innate and adaptative immune population in the for-
eign body response against hydrogels, without the need of
immune suppression, while the presence of protein-coated
GO nanoparticles does not induce a higher immune
response. We can conclude that protein-coated GO nanopar-
ticles provide a suitable microenvironment for encapsulated
cells and represent a good alternative to improve the
sustained drug release from microcapsules, with better out-
comes in the more extensively evaluated 380 mm diameter
microcapsules.
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